Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2020-07-01 Transaction in Own Shar…
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Acquisition ou cession des actions de l'émetteur / Descriptif du programme de rachat
Transaction in Own Shares Classification · 98% confidence The document is titled "Descriptif du programme de rachat d'actions" (Description of the share repurchase program) and details the objectives, terms, maximum price, and duration for Mauna Kea Technologies to buy back its own shares. This activity directly relates to the company's capital structure management and share transactions. This aligns perfectly with the definition for 'Transaction in Own Shares' (Code: POS), which covers share repurchase programs. It is not a general financing update (CAP) but a specific plan for repurchasing shares.
2020-07-01 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated June 24, 2020, announcing the launch of a clinical study combining robotic bronchoscopic navigation and laser confocal endomicroscopy for peripheral lung nodules. It details the collaboration, the technology involved (Cellvizio®, Monarch™), the study's objective (feasibility and safety), and includes quotes from involved physicians and the CEO. This type of announcement, detailing a specific operational or clinical development, is characteristic of a general press release or regulatory filing that doesn't fit the specific financial report categories (like 10-K, ER, IR). Since it is a specific announcement about a clinical trial launch and partnership, it is best classified as a general Regulatory Filing (RNS) as it is a public disclosure of a significant event, or potentially a Legal Proceedings Report (LTR) if it were about litigation, but here it is about a study. Given the options, RNS serves as the best general regulatory announcement fallback for non-standard disclosures like this clinical trial launch announcement, although it is not a standard financial report. The document length (7191 chars) is substantial enough that it is the report itself, not just an announcement of a report (RPA).
2020-06-24 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated June 24, 2020, announcing a significant operational event: the launch of a First in Human clinical study combining specific medical technologies (Robotic Navigational Bronchoscopy and Needle-Based Confocal Laser Endomicroscopy). This type of announcement, detailing business developments, collaborations, and clinical milestones, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a management discussion (MDA), or a specific capital event (CAP, SHA), and it is a direct announcement of a business/operational update, it fits best under the Earnings Release category if it were tied to a reporting period, or RNS if it's a general corporate update. Given the content is a major operational announcement rather than a summary of financial results, and it doesn't fit the other specific categories, it is classified as a general Regulatory Filing (RNS). However, press releases announcing major operational news often accompany or precede formal earnings reports, making ER a possibility, but RNS is the safer general category for non-financial, non-meeting related corporate news that must be disclosed. Since it is a detailed announcement of a clinical study launch, it is a significant corporate event disclosure, which often falls under RNS when no other specific category applies. It is not a Report Publication Announcement (RPA) because it is the news itself, not an announcement *about* another report.
2020-06-24 English
Rapport financier annuel 2019
Annual Report Classification · 100% confidence The document is titled 'Rapport Financier Annuel 2019' (Annual Financial Report 2019) and contains a comprehensive summary including management reports, consolidated financial statements, audit reports, and governance information for the fiscal year 2019. It is a full-length annual report, not an announcement or a summary, and it contains substantive financial data and analysis. FY 2019
2020-06-05 French
Modalités de mise à disposition des documents préparatoires à l'AG
Proxy Solicitation & Information Statement Classification · 98% confidence The document is a press release from Mauna Kea Technologies informing shareholders about the voting procedures and participation methods for its upcoming 'assemblée générale mixte' (Combined General Meeting) scheduled for July 2, 2020. Key phrases include 'informe ses actionnaires des modalités de vote et de participation à son assemblée générale mixte' and details on how to vote remotely ('vote par correspondance'). This content directly relates to the logistics, rules, and information provided to shareholders ahead of a general meeting, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). While it concerns the AGM, it is the notice/information package regarding the meeting logistics, not the final voting results (DVA) or the meeting presentation itself (AGM-R).
2020-05-27 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated March 3, 2020, announcing that Mauna Kea Technologies has received FDA 510(k) clearance and CE marking for its next-generation Cellvizio® platform. This type of announcement, detailing regulatory milestones, product updates, and future commercialization plans, is characteristic of an Earnings Release (ER) or a general regulatory/corporate announcement. Since it focuses on a specific, positive regulatory event (FDA/CE approval) rather than comprehensive financial results (10-K, IR) or a management/board change (MANG), it fits best as an Earnings Release (ER) which often includes significant operational news alongside financial context, or potentially a Regulatory Filing (RNS) if it were purely a notification. Given the structure and content (product details, quotes from the CEO, forward-looking statements), it functions as a key operational update often bundled with earnings cycles, but the core event is a regulatory clearance. However, none of the definitions perfectly capture a 'Regulatory Approval Announcement' outside of RNS. Since it is a formal announcement of a significant business event (FDA clearance) and not a full financial report, ER is a strong candidate if it precedes the full results, or RNS as a general regulatory filing. Given the context of financial reporting databases, major regulatory approvals that impact commercialization are often classified under ER if they are time-sensitive announcements, or RNS if they are purely regulatory filings. Since it is a press release announcing a major operational milestone, ER (Earnings Release, often used broadly for key operational updates) or RNS (Regulatory Filings) are the closest. I will lean towards RNS as it is a specific regulatory clearance announcement that doesn't contain the full financial statements typical of an ER, and RNS is the general regulatory fallback.
2020-03-03 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.